Profil
Pieter Spee is currently the Chief Scientific Officer at Pure Biologics SA since 2023.
Prior to this, he worked as the Scientific Director-Translational Immunology at Novo Nordisk A, Chief Scientific Officer at TikoMed AB, and Chief Technology Officer at FibroTx OÜ.
He obtained his doctorate degree from the University of Leiden in 1996.
Aktive Positionen von Pieter Spee
| Unternehmen | Position | Beginn |
|---|---|---|
| PURE BIOLOGICS S.A. | Technik-/Wissenschafts-/F&E-Leiter | 26.05.2023 |
Ehemalige bekannte Positionen von Pieter Spee
| Unternehmen | Position | Ende |
|---|---|---|
FibroTx OÜ | Technik-/Wissenschafts-/F&E-Leiter | - |
TikoMed AB
TikoMed AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Technik-/Wissenschafts-/F&E-Leiter | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Ausbildung von Pieter Spee
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
University of Leiden
University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TikoMed AB
TikoMed AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Pure Biologics SA
Pure Biologics SA BiotechnologyHealth Technology Operates as a a biopharmaceutical company which develops biological medicines, diagnostic tests and medical devices with therapeutic use | Health Technology |
FibroTx OÜ |
















